A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.
Hui Fang
Advertisement
Hui Fang is a senior scientist at Eisai.
Articles by Hui Fang
Advertisement
Latest Updated Articles
Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based ApproachPublished: October 2nd 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Key Trends Driving Supply Chain Localization and Data Scrutiny in Biopharma
2
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
3
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
4
Turning Real-World Data into Actionable Drug Development Insights With AI
5
